4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists
摘要:
A series of 4-(3-aryloxyaryl)quinolines with sulfone substituents on the terminal aryl ring (7) was prepared as LXR agonists. High affinity LXR ligands with excellent agonist potency and efficacy in functional assays of LXR activity were identified. In general, these sulfone agonists were equal to or superior to previously described alcohol and amide analogs in terms of affinity, functional potency, and microsomal stability. Many of the sulfones had LXR beta binding IC(50) values <10 nM while the most potent compounds in an ABCA1 mRNA induction assay in J774 mouse cells had EC(50) values <10 nM and were as efficacious as T0901317. (C) 2009 Elsevier Ltd. All rights reserved.
Quinolines useful in treating cardiovascular disease
申请人:Collini D. Michael
公开号:US20050131014A1
公开(公告)日:2005-06-16
This invention provides compounds of formula I
that are useful in the treatment or inhibition of LXR mediated diseases.
本发明提供了式I化合物的用途,它们在治疗或抑制LXR介导的疾病中是有用的。
QUINOLINE COMPOUNDS
申请人:Wyeth
公开号:EP2074098A2
公开(公告)日:2009-07-01
US7576215B2
申请人:——
公开号:US7576215B2
公开(公告)日:2009-08-18
[EN] QUINOLINE COMPOUNDS<br/>[FR] COMPOSÉS DE QUINOLÉINE
申请人:WYETH CORP
公开号:WO2008049047A2
公开(公告)日:2008-04-24
[EN] This invention relates generally to quinoline-based modulators of Liver X receptors (LXRs) and related methods. [FR] La présente invention concerne de manière générale des modulateurs à base de quinoléine des récepteurs X du foie (LXR) et des procédés associés.